Literature DB >> 9932713

Vasopressin receptor antagonist OPC-31260 prevents cerebral oedema after subarachnoid haemorrhage.

F A László1, C Varga, S Nakamura.   

Abstract

The effects of the non-peptide vasopressin V2 receptor antagonist, 5-dimethylamino-1-[4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrah ydro-1 H-benzazepine hydrochloride (OPC-31260) on the cerebral oedema induced by subarachnoid haemorrhage were studied in rats. Subarachnoid haemorrhage induced significant water retention after water loading, increased the brain content of water and Na+ and increased plasma vasopressin levels. The water retention and brain water and Na+ accumulation were prevented by OPC-31260 administration, but the plasma vasopressin levels were further enhanced by OPC-31260. These results demonstrate the important role of vasopressin in the development of antidiuresis and disturbances in brain water and electrolyte balance in response to subarachnoid haemorrhage. The subarachnoid haemorrhage-induced cerebral oedema was significantly reduced following oral OPC-31260 administration. The protective mechanism exerted by OPC-31260 stems from its influence on renal tubular function: it blocks the renal vasopressin V2 receptors. These observations might suggest a new, effective approach to the treatment of subarachnoid haemorrhage-induced cerebral oedema in humans.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9932713     DOI: 10.1016/s0014-2999(98)00836-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Targeted over-expression of endothelin-1 in astrocytes leads to more severe brain damage and vasospasm after subarachnoid hemorrhage.

Authors:  Patrick K K Yeung; Jiangang Shen; Stephen S M Chung; Sookja K Chung
Journal:  BMC Neurosci       Date:  2013-10-25       Impact factor: 3.288

Review 2.  Treatment of stroke related refractory brain edema using mixed vasopressin antagonism: a case report and review of the literature.

Authors:  Vishnumurthy Shushrutha Hedna; Sharathchandra Bidari; David Gubernick; Saeed Ansari; Irawan Satriotomo; Asif A Khan; Adnan I Qureshi
Journal:  BMC Neurol       Date:  2014-11-18       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.